Genetic Testing to Guide Risk-Stratified Screens for Breast Cancer
Open Access
- 1 March 2019
- journal article
- review article
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 9 (1) , 15
Abstract
Breast cancer screening modalities and guidelines continue to evolve and are increasingly based on risk factors, including genetic risk and a personal or family history of cancer. Here, we review genetic testing of high-penetrance hereditary breast and ovarian cancer genes, including BRCA1 and BRCA2, for the purpose of identifying high-risk individuals who would benefit from earlier screening and more sensitive methods such as magnetic resonance imaging. We also consider risk-based screening in the general population, including whether every woman should be genetically tested for high-risk genes and the potential use of polygenic risk scores. In addition to enabling early detection, the results of genetic screens of breast cancer susceptibility genes can be utilized to guide decision-making about when to elect prophylactic surgeries that reduce cancer risk and the choice of therapeutic options. Variants of uncertain significance, especially missense variants, are being identified during panel testing for hereditary breast and ovarian cancer. A finding of a variant of uncertain significance does not provide a basis for increased cancer surveillance or prophylactic procedures. Given that variant classification is often challenging, we also consider the role of multifactorial statistical analyses by large consortia and functional tests for this purpose.Keywords
Funding Information
- U.S. Department of War (W81XWH-18-1-0269)
- National Institutes of Health (1R01CA215151)
This publication has 151 references indexed in Scilit:
- ENIGMA-Evidence-based network for the interpretation of germline mutant alleles: An international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genesHuman Mutation, 2011
- Discriminatory accuracy and potential clinical utility of genomic profiling for breast cancer risk in BRCA-negative womenBreast Cancer Research and Treatment, 2010
- Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and MortalityJAMA, 2010
- Performance of Common Genetic Variants in Breast-Cancer Risk ModelsNew England Journal of Medicine, 2010
- Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test resultsHuman Mutation, 2008
- Mouse embryonic stem cell–based functional assay to evaluate mutations in BRCA2Nature Medicine, 2008
- A Systematic Genetic Assessment of 1,433 Sequence Variants of Unknown Clinical Significance in the BRCA1 and BRCA2 Breast Cancer–Predisposition GenesThe American Journal of Human Genetics, 2007
- The BOADICEA model of genetic susceptibility to breast and ovarian cancerBritish Journal of Cancer, 2004
- A breast cancer prediction model incorporating familial and personal risk factorsStatistics in Medicine, 2004
- Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2Nature Genetics, 1996